Related Experiment Video
Updated: Jul 16, 2026
07:50
Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic
1Health Protection Agency Centre for Infections, Department of Healthcare-Associated Infection and Antimicrobial Resistance, 61 Colindale Avenue, London NW9 5EQ, UK. alan.johnson@hpa.org.uk
Current Opinion in Investigational Drugs (London, England : 2000)
|March 3, 2007
Summary
Optimer Pharmaceuticals is developing OPT-80, a novel macrocyclic antibiotic, for treating Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infections. Clinical trials are currently evaluating OPT-80
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus (VRE) are significant healthcare-associated infections.
- Existing treatments for these infections face challenges with resistance and recurrence.
- Novel therapeutic agents are needed to combat these resistant pathogens.
Purpose of the Study:
- To evaluate the efficacy and safety of OPT-80, a novel macrocyclic antibiotic, for the treatment of CDAD.
- To explore the potential of OPT-80 against vancomycin-resistant Enterococcus infections.
Main Methods:
- OPT-80 is a narrow-spectrum macrocyclic antibiotic derived from Dactylosporangium aurantiacum.
- A Phase IIb/III clinical trial is currently investigating OPT-80 in patients diagnosed with CDAD.
- In vitro studies may be assessing activity against vancomycin-resistant Enterococcus.
Main Results:
- Data from the ongoing Phase IIb/III trial will determine the efficacy of OPT-80 in CDAD patients.
- Preliminary data on OPT-80's activity against VRE may be available.
- Safety and tolerability profiles are being assessed during clinical trials.
Conclusions:
- OPT-80 shows promise as a potential new treatment for CDAD.
- Further clinical evaluation is required to establish OPT-80's role in treating CDAD and VRE infections.
- Successful development of OPT-80 could offer a valuable therapeutic option against challenging bacterial infections.
More Related Videos
Related Concept Videos
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
00:57Antibiotic Selection
Overview
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...